<--- Back to Details
First PageDocument Content
Biology / Developmental biology / Stem cells / Emerging technologies / Induced stem cells / Biotechnology / Regenerative medicine / RIKEN / Clinical trial / Macular degeneration / Induced pluripotent stem cell
Date: 2015-11-24 20:24:40
Biology
Developmental biology
Stem cells
Emerging technologies
Induced stem cells
Biotechnology
Regenerative medicine
RIKEN
Clinical trial
Macular degeneration
Induced pluripotent stem cell

November 25, 2015 Foundation for Biomedical Research and Innovation RIKEN Kobe City Medical Center General Hospital Termination of subject enrollment for the “Clinical study of autologous induced pluripotent stem cell-

Add to Reading List

Source URL: www.riken-ibri.jp

Download Document from Source Website

File Size: 87,71 KB

Share Document on Facebook

Similar Documents

China Regenerative Medicine International Limited 中國再生醫學國際有限公司 Incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立之有限公司 Stock Code 股份代號:8158

China Regenerative Medicine International Limited 中國再生醫學國際有限公司 Incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立之有限公司 Stock Code 股份代號:8158

DocID: 1vnZo - View Document

[For immediate release]  [Press Release] China Regenerative Medicine International Limited (Stock Code: 8158.HK)

[For immediate release] [Press Release] China Regenerative Medicine International Limited (Stock Code: 8158.HK)

DocID: 1vlMf - View Document

Centre for Cell Therapy and Regenerative Medicine 6th Margaret River Region Forum and 9th ASSCR Annual Scientific Meeting Stem Cells: Fundamental Biology and Clinical Translation

Centre for Cell Therapy and Regenerative Medicine 6th Margaret River Region Forum and 9th ASSCR Annual Scientific Meeting Stem Cells: Fundamental Biology and Clinical Translation

DocID: 1v4Rh - View Document

May 24, 2018  CollPlant Reports First Quarter 2018 Financial Results and Provides Business Update NESS ZIONA, Israel, May 24, 2018 /PRNewswire/ -CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company util

May 24, 2018 CollPlant Reports First Quarter 2018 Financial Results and Provides Business Update NESS ZIONA, Israel, May 24, 2018 /PRNewswire/ -CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company util

DocID: 1uYu4 - View Document

China Regenerative Medicine International Limited 中國再生醫學國際有限公司  Annual Report 年報

China Regenerative Medicine International Limited 中國再生醫學國際有限公司 Annual Report 年報

DocID: 1uNPZ - View Document